Top

Breast Cancer

Published in:

01-11-2015 | Original Article

EIF5A2 is a novel chemoresistance gene in breast cancer

Authors: Yu Liu, Feiya Du, Wei Chen, Minya Yao, Kezhen Lv, Peifen Fu

Published in: Breast Cancer | Issue 6/2015

Abstract

Background

The eIF5A2 gene (encoding the eukaryotic initiation factor 5A2) located at 3q26 is a putative oncogene that is overexpressed in colon and rectal carcinomas, lung cancer and hepatocellular carcinoma. EIF5A2 overexpression correlates significantly with tumor metastasis and is an adverse prognostic marker. However, eIF-5A2 overexpression in breast cancer and its effect on chemotherapy are unknown.

Methods

We measured eIF-5A2 expression and doxorubicin sensitivity in different human breast cancer cell lines (Bcap-1937, HCC1937, and MCF-7). To investigate a role for eIF-5A2 in chemoresistance, cells were treated with eIF-5A2-siRNA, exposed to various concentrations of doxorubicin, and toxicity was assayed by CCK-8 (cell counting kit).

Results

The eIF-5A2 expression levels varied among breast cancer cells. Higher expression levels correlated with decreased doxorubicin sensitivity. Silencing of eIF-5A2 significantly improved doxorubicin toxicity in all three breast cancer cell lines.

Conclusion

This study shows that eIF-5A2 plays an important role in doxorubicin chemoresistance in breast cancer cells.

Howlader N, Noone AM, Krapcho M: SEER CancerStatistics Review, 1975–2008, National Cancer Institute.Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER website. http://seer.cancer.gov/csr/1975_2008/ (2011).

Christensen LA, Finch RA, Booker AJ, Vasquez KM. Targeting oncogenes to improve breast cancer chemotherapy. Cancer Rese. 2006;66:4089–94.CrossRef

Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, et al. Targeting NF κB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther. 2011;11:678–89.PubMedCentralCrossRefPubMed

He QJ, Zeng WF, Sham JS, Xie D, Yang XW, Lin HL, et al. Recurrent genetic alterations in 26 colorectal carcinomas and 21 adenomas from Chinese patients. Cancer Genet Cytogenet. 2003;144:112–8.CrossRefPubMed

Ried T, Knutzen R, Steinbeck R, Blegen H, Schröck E, Heselmeyer K, du Manoir S, Auer G. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosome Cancer. 1996;15:234–45.CrossRef

Sham JS, Tang TC, Fang Y, Sun L, Qin LX, Wu QL, Xie D, Guan XY. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet. 2002;133:39–44.CrossRefPubMed

Kettunen E, El-Rifai W, Björkqvist AM, Wolff H, Karjalainen A, Anttila S, et al. A broad amplification pattern at 3q in squamous cell lung cancer e a fluorescence in situ hybridization study. Cancer Genet Cytogenet. 2000;117:66–70.CrossRefPubMed

Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P, et al. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent patter n of chromosomal alterations. Genes Chromosome Cancer. 1999;25:160–8.CrossRef

Guan XY, Fu SB, Xia JC, Fang Y, Sham JS, Du BD, et al. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet. 2000;123:27–34.CrossRefPubMed

10.

Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, et al. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer. 2004;4:5.PubMedCentralCrossRefPubMed

11.

Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate. 1999;39:79–86.CrossRefPubMed

12.

Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, van Beers E, et al. Gene expression signatures in breast cancer patients integration of DNA copy number alterations and prognostic. Clin Cancer Res. 2010;16:651–63.CrossRefPubMed

13.

Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 2001;61:3806–9.PubMed

14.

Guan XY, Fung JM, Ma NF, Lau SH, Tai LS, Xie D, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Res. 2004;64:4197–200.CrossRefPubMed

15.

Lee NP, Tsang FH, Shek FH, Mao M, Dai H, Zhang C, et al. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma. Int J Cancer. 2010;127:968–76.CrossRefPubMed

16.

Yang GF, Xie D, Liu JH, Luo JH, Li LJ, Hua WF, et al. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new in dependent predictor of outcome in patients with ovarian carcinoma. Gynecol Oncol. 2009;112:314–8.CrossRefPubMed

17.

Luo JH, Hua WF, Rao HL, Liao YJ, Kung HF, Zeng YX, et al. Overexpression of EIF-5A2 predict s tumor recurrence and progression in pTa/pT1 urothelial carcinoma of the bladder. Cancer Sci. 2009;100:896–902.CrossRefPubMed

18.

He LR, Zhao HY, Li BK, Liu YH, Liu MZ, Guan XY, et al. Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non–small cell lung cancer patients. Int J Cancer. 2011;129:143–50.CrossRefPubMed

19.

Tang DJ, Dong SS, Ma NF, Xie D, Chen L, Fu L, et al. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology. 2010;51:1255–63.CrossRefPubMed

20.

Zhu W, Cai MY, Tong ZT, Dong SS, Mai SJ, Liao YJ, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial mesenchymal transition. Gut. 2012;61:562–75.CrossRefPubMed

21.

Zeng C, Liu Y, Hu YZ, Zhao QB, Chi SM. Inhibitory effect of Rab23 on growth and proliferation of breast cancer cells. Prog Mod Biomed. 2009;20:3811–5.

22.

Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61:6747–54.PubMed

23.

Rowe DL, Ozbay T, O’Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer. 2009;3:61–75.PubMedCentralPubMed

24.

Cooper HL, Park MH, Folk JE. Posttranslational formation of hypusine in a single major protein occurs generally in growing cells and is associated with activation of lymphocyte growth. Cell. 1982;29:791–7.CrossRefPubMed

25.

Schnier J, Schwelberger HG, Smit-McBride Z, Kang HA, Hershey JW. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae. Mol Cell Biol. 1991;11:3105–14.PubMedCentralCrossRefPubMed

26.

Wohl T, Klier H, Ammer H, Lottspeich F, Magdolen V. The HYP2 gene of Saccharomyces cerevisiae is essential for aerobic growth: characterization of different isoforms of the hypusine-containing protein Hyp2p and analysis of gene disruption mutants. Mol Gen Genet. 1993;241:305–11.PubMed

27.

Benne R, Hershey JW. The mechanism of action of protein synthesis initiation factors from rabbit reticulocytes. J Biol Chem. 1978;253:3078–87.PubMed

28.

Kang HA, Hershey JW. Effect of initiation factor eIF-5A depletion on protein synthesis and proliferation of Saccharomyces cerevisiae. J Biol Chem. 1994;269:3934–40.PubMed

29.

Xu A, Jao DL, Chen KY. Identification of mRNA that binds to eukaryotic initiation factor 5A by affinity co-purification and differential display. Biochem J. 2004;384:585–90.PubMedCentralCrossRefPubMed

30.

Zanelli CF, Valentini SR. Pkc1 acts throug h Zds1 and Gic1 to sup-press growth and cell polarity defects of a yeast eIF5A mutant. Genetics. 2005;171:1571–81.PubMedCentralCrossRefPubMed

31.

Smit-McBride Z, Dever TE, Hershey JW, Merrick WC. Sequence determination and cDNA cloning of eukar yotic initiation factor 4D, the hypusine-containing protein. J Biol Chem. 1989;264:1578–83.PubMed

32.

Koettnitz K, Wohl T, Kappel B, Lottspeich F, Hauber J, Bevec D. Identification of a new member of the human eIF-5A gene family. Gene. 1995;159:283–4.CrossRefPubMed

33.

Clement PM, Henderson CA, Jenkins ZA, Smit-McBride Z, Wolff EC, Hershey JW, et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur J Biochem. 2003;270:4254–63.CrossRefPubMed

34.

Jenkins ZA, Haag PG, Johansson HE. Human eIF5A2 on chromo-some 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics. 2001;71:101–9.CrossRefPubMed

35.

Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun. 2012;417:679–85.CrossRefPubMed

36.

Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer. 2013;49:520–30.CrossRefPubMed

37.

Güngör C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, et al. Notch signaling activated by replication stress-induced expression of midline drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011;71:5009–19.CrossRefPubMed

38.

Chen X, Lingala S, Khoobyari S, Nolta J, Zern MA, Wu J. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol. 2011;55:838–45.PubMedCentralCrossRefPubMed

Title: EIF5A2 is a novel chemoresistance gene in breast cancer
Authors: Yu Liu
Feiya Du
Wei Chen
Minya Yao
Kezhen Lv
Peifen Fu
Publication date: 01-11-2015
Publisher: Springer Japan
Published in: Breast Cancer / Issue 6/2015
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-014-0526-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2015

Adult BMI change and risk of Breast Cancer: National Health and Nutrition Examination Survey (NHANES) 2005–2010

A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG

Detection of breast cancer from blood through analysis of lymphocyte fluorescent intensity using MUC1 antigen

Acknowledgement to reviewers 2015

Epidemiology of ductal carcinoma in situ in Western Australia: implications for surgical margins and management

Keynote webinar | Spotlight on antibody–drug conjugates in cancer